U.S., May 3 -- ClinicalTrials.gov registry received information related to the study (NCT06955260) titled 'SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure' on March 15.
Brief Summary: Some people are born with a birth defect where they only have one functioning ventricle (lower chamber) in their heart. This condition can be initially managed with a Fontan operation, but there is a risk of developing Fontan Circulatory Failure (FCF) later in life. FCF occurs when the single working heart ventricle is no longer strong enough to pump blood throughout the body. This also means the heart has difficulty supplying oxygen to keep up with the needs of the body. As a result, individuals living with FCF may have some challenges carr...